Lucid Group Inc vs Neurocrine Biosciences Inc — how do they compare? Lucid Group Inc trades at $6.38 (market cap $2.64B), while Neurocrine Biosciences Inc trades at $158.43 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.2× Lucid Group Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| LCID | NBIX | |
|---|---|---|
Market Cap | $2.64B | $16.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.77 | $185.50 |
52-Week Low | $4.62 | $123.10 |
Enterprise Value | $5.54B | $16.48B |
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $6.61, down 6.11% amid ongoing operational challenges. The stock shows bearish technical signals with negative moving averages and faces fundamental headwinds including consistent quarterly losses, negative profit margins, and substantial cash burn. Recent news highlights an operational reset targeting $1.4 billion in cash improvements and delays to the affordable Cosmos EV launch to 2027.
The outlook remains challenging with deep losses and cash burn overshadowing revenue growth. Analyst consensus is cautious with 67% hold ratings, though the $10.50 price target suggests potential upside. Key risks include execution of turnaround plans, intense EV competition, and funding needs. The stock's direction hinges on successful cost reductions and future product execution.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →